Brigham and Women's Hospital
Primary sclerosing cholangitis (PSC) is a chronic disease that causes inflammation and scarring of the bile ducts and can lead to progressive liver damage. There are currently no approved medications that have been shown to improve long-term outcomes in patients with PSC. The purpose of this pilot study is to evaluate whether N-acetylcysteine (NAC), a medication that helps the body produce an antioxidant called glutathione, may improve liver blood tests in people with PSC. This is a single-center, open-label study involving approximately 15 adults with PSC. All participants will receive oral NAC at a dose of 1,200 mg per day for the first 12 weeks. At Week 12, the dose will either remain the same or increase to 1,800 mg per day, depending on changes in a liver blood test called alkaline phosphatase (ALP). Participants will continue treatment through Week 16. Those with a substantial improvement in ALP may be eligible to continue treatment through Week 20. Researchers will evaluate changes in liver blood tests, treatment safety, side effects, and medication adherence. Additional blood tests may help researchers better understand how NAC affects liver injury. This study is intended to provide preliminary information about the potential benefits and safety of NAC in PSC. It is not designed to establish whether NAC is an effective treatment for PSC.
This is a prospective, single-center, open-label, single-arm, response-adaptive pilot study designed to assess the biochemical effects, safety, and tolerability of oral N-acetylcysteine (NAC) monotherapy in adults with primary sclerosing cholangitis (PSC). The study will enroll approximately 15 participants at Brigham and Women's Hospital. All enrolled participants will receive NAC 600 mg orally twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in serum alkaline phosphatase (ALP) of at least 40% from baseline will continue receiving 1,200 mg/day. Pa…
\*\*Inclusion Criteria:\*\* * Adults aged 18 to 70 years. * Diagnosis of primary sclerosing cholangitis (PSC) for at least 6 months, confirmed by characteristic cholangiographic findings, without evidence of secondary sclerosing cholangitis. * Serum alkaline phosphatase (ALP) greater than 1.33 times the upper limit of normal at screening. * Platelet count greater than 150,000/mm³, serum albumin greater than 3.3 g/dL, and serum creatinine below the upper limit of normal. * For participants receiving ursodeoxycholic acid (UDCA), a stable dose for at least 3 months before screening. Participants…
N-Acetylcysteine (NAC) will be administered orally at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in serum alkaline phosphatase (ALP) of at least 40% from baseline will continue receiving 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day for Weeks 12-16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue NAC treatment through Week 20, according to the protocol. The intervention will be administered as oral 600 mg capsules.